Namasté Solar Namasté Solar

Namasté Solar

9B10M049

    • £1.99
    • £1.99

Publisher Description

Should a fast-growing, employee-owned solar electric company accept a buyout offer from a private equity investor? Could it do so without sacrificing its distinctive, high-involvement culture? Namasté Solar, a 55-person firm based in Boulder, Colorado, designed and installed solar electric systems for residential, commercial, non-profit and government customers. In 2008, the company had been growing at breakneck speed for the past four years, since government incentives for the purchase of renewable energy had created a market for solar electric systems in Colorado. Now, two investors had approached the firm with serious buyout offers. A buyout would bring a new infusion of capital to the firm, enabling it to expand more quickly and install more solar systems, and employees with vested shares would benefit from an attractive sales price. However, Namasté, from the outset, had been committed to building a democratic, high-involvement culture. Ownership was widely shared, and all employees, whether or not they held equity, were encouraged to participate in strategic decisions facing the firm. Many were concerned that selling the company would mean sacrificing the firm's carefully crafted culture. What was the best way forward for Blake Jones and the green energy company that he and two partners had founded?

GENRE
Business & Personal Finance
RELEASED
2010
5 July
LANGUAGE
EN
English
LENGTH
12
Pages
PUBLISHER
Richard Ivey School of Business Foundation
SIZE
378.6
KB

More Books Like This

How I Did It How I Did It
2014
Think Big, Act Small Think Big, Act Small
2005
Start. Scale. Sell. Start. Scale. Sell.
2020
Reimagining Work Reimagining Work
2017
RADICAL Companies RADICAL Companies
2021
Partners on the Payroll Partners on the Payroll
2022

More Books by Anne T. Lawrence

On Dark and Bloody Ground On Dark and Bloody Ground
2021
Farming Pharmaceuticals: Ventria Bioscience and the Controversy over Plant-made Medicines Farming Pharmaceuticals: Ventria Bioscience and the Controversy over Plant-made Medicines
2009